Table II.
Demographic and clinical characteristics of COVID-19–positive patients stratified by DVT and PE
| Characteristic | DVT/PE |
P value | |
|---|---|---|---|
| No (n = 833) | Yes (n = 82) | ||
| Male sex | 469 (56.3) | 50 (61.0) | .485 |
| Age, years | 61.0 (50.0-73.0) | 61.5 (50.2-73.8) | .764 |
| Congestive heart failure | 89 (10.7) | 10 (12.2) | .827 |
| Hypertension | 440 (52.9) | 39 (47.6) | .414 |
| Coronary artery disease | 108 (13.0) | 11 (13.4) | 1.000 |
| Myocardial infarction | 27 (3.3) | 5 (6.2) | .195 |
| Diabetes mellitus | 297 (35.8) | 27 (32.9) | .074 |
| Chronic kidney disease | 125 (15.0) | 13 (15.9) | .973 |
| Peripheral vascular disease | 33 (4.0) | 2 (2.4) | .784 |
| Ischemic stroke | 40 (4.8) | 1 (1.2) | .310 |
| Transient ischemic attack | 14 (1.7) | 0 (0) | .692 |
| Intracerebral hemorrhage | 2 (0.2) | 0 (0) | 1.000 |
| Atrial fibrillation | 116 (10.0) | 11 (13.4) | .310 |
| Hyperlipidemia | 337 (40.6) | 32 (39.0) | .873 |
| Antihypertensive medication | 403 (50.8) | 33 (43.4) | .359 |
| Lipid-lowering medication | 328 (41.2) | 23 (30.3) | .148 |
| Antiplatelet medication | 250 (31.5) | 15 (19.7) | .076 |
| CHA2DS2VASc score | 2.00 (1.00-3.00) | 2.00 (1.00-3.00) | .299 |
| Endotracheal mechanical ventilation | 44 (6.0) | 8 (15.7) | .015 |
| BMI, kg/m2 | 28.7 (25.2-35.3) | 28.2 (25.3-34.6) | .587 |
| ≥2 criteria of SIRS | 213 (23.3) | 34 (45.3) | .010 |
| WBC count,a 109/L | 6.30 (4.70-8.70) | 8.40 (5.7-11.2) | <.001 |
| Hemoglobin, g/dL | 13.1 (11.5-14.3) | 12.4 (10.5-14.0) | .022 |
| Hematocrit, % | 39.1 (35.2-42.8) | 37.6 (32.5-42.2) | .029 |
| Platelet count,b 109/L | 199 (151-255) | 230 (168-304) | .002 |
| Albumin, g/dL | 3.60 (3.20-3.90) | 3.40 (2.98-3.80) | .012 |
| Creatinine, mg/dL | 0.90 (0.73-1.21) | 0.89 (0.75-1.29) | .523 |
| PT, seconds | 13.3 (12.4-14.8) | 14.3 (12.9-17.6) | .006 |
| aPTT, seconds | 31.0 (29.0-35.0) | 33.0 (30.0-54.0) | .025 |
| INR | 1.2 (1.10-1.30) | 1.30 (1.10-1.50) | .003 |
| D-dimer,c ng/mL | 675 (466-1141) | 2112 (969-13,286) | <.001 |
| Ferritin,d μg/L | 514 (226-968) | 448 (238-1076) | .927 |
| C-reactive protein, mg/L | 70.7 (34.0-128) | 74.4 (41.7-159) | .170 |
| Probrain natriuretic peptide, pg/mL | 230 (68.0-938) | 754 (207-3155) | <.001 |
| Interleukin-6, pg/mL | 17.9 (8.50-34.5) | 25.1 (14.3-150) | .002 |
| Procalcitonin, ng/mL | 0.15 (0.09-0.35) | 0.23 (0.13-0.51) | .005 |
| Anticoagulation therapy | 0 (0) | 82 (100) | NA |
aPTT, Activated partial thromboplastin time; BMI, body mass index; CHA2DS2VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65-74 years, sex category; COVID-19, coronavirus disease 2019; DVT, deep vein thrombosis; INR, international normalized ratio; NA, not applicable; PE, pulmonary embolism; PT, prothrombin time; SIRS, systemic inflammatory response syndrome; WBC, white blood cell.
Data presented as number (%) or median (interquartile range).
a
Normal range, 3.4-9.6 × 109/L.
b
Normal range, 135-317 × 109/L.
c
Normal range, ≤500 mg/mL.
d
Normal range, 24-337 μg/L.